☰

Cheng-Lung Hsu, Ph.D. - Publications

Affiliations: 
2004 University of Rochester, Rochester, NY 
Area:
Molecular Biology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, Chang C. Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382. PMID 33453984 DOI: 10.1074/jbc.AAC120.016763  0.806
2020 Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, Chang C. Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382. PMID 33310747 DOI: 10.1074/jbc.AAC120.016763  0.806
2020 Huang WK, Liu CH, Pang ST, Liu JR, Chang JW, Liaw CC, Hsu CL, Lin YC, See LC. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan. Jama Network Open. 3: e2015189. PMID 32865575 DOI: 10.1001/jamanetworkopen.2020.15189  0.31
2017 Hsu CL, Liu JS, Lin TW, Chang YH, Kuo YC, Lin AC, Ting HJ, Pang ST, Lee LY, Ma WL, Lin CC, Wu WG. Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget. 8: 69508-69519. PMID 29050220 DOI: 10.18632/oncotarget.17843  0.829
2017 Hsu CL, Liu JS, Lin TW, Chang YH, Kuo YC, Lin AC, Ting HJ, Pang ST, Lee LY, Ma WL, Lin CC, Wu WG. Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget. PMID 28562322 DOI: 10.18632/oncotarget.17843  0.829
2016 Lai HC, Yeh CC, Jeng LB, Huang SF, Liao PY, Lei FJ, Cheng WC, Hsu CL, Cai X, Chang C, Ma WL. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget. PMID 27340775 DOI: 10.18632/Oncotarget.10186  0.715
2016 Dong YH, Chang CH, Gagne JJ, Hsu CL, Lai MS. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. Pharmacotherapy. 36: 26-37. PMID 26799347 DOI: 10.1002/phar.1684  0.307
2014 Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, Ting HJ, Pang ST, Yeh SD, Ma WL, Chen CJ, Wu WG, Chang C. Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. Molecular Oncology. 8: 1575-87. PMID 25091737 DOI: 10.1016/J.Molonc.2014.06.009  0.805
2014 Hsu CL, Liu JS, Lin AC, Yang CH, Chung WH, Wu WG. Minoxidil may suppress androgen receptor-related functions. Oncotarget. 5: 2187-97. PMID 24742982  0.475
2013 Hsu CL, Chang CH, Lin JW, Wu LC, Chuang LM, Lai MS. Histamine-2 receptor antagonists and risk of lung cancer in diabetic patients – an exploratory analysis. Pharmacoepidemiology and Drug Safety. 22: 632-40. PMID 23576472 DOI: 10.1002/pds.3441  0.433
2012 Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology (Baltimore, Md.). 56: 176-85. PMID 22318717 DOI: 10.1002/Hep.25644  0.791
2010 Chen CY, Hsu CL, Chang CH, Chen KY, Yu CJ, Yang PC. Hemothorax in a medical intensive care unit: incidence, comorbidity and prognostic factors. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 109: 574-81. PMID 20708508 DOI: 10.1016/S0929-6646(10)60094-0  0.314
2010 Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Science Translational Medicine. 2: 32ra35. PMID 20484730 DOI: 10.1126/Scitranslmed.3001143  0.725
2010 Ma W, Hsu C, Wu M, Huang C, Hsu J, Chen C, Wu C, Chang C. Abstract 2917: Novel function of androgen receptor: Cancer suppressor in hepatocellular carcinoma Cancer Research. 70: 2917-2917. DOI: 10.1158/1538-7445.Am10-2917  0.76
2009 Hsu CL, Chang CH, Wong KN, Chen KY, Yu CJ, Yang PC. Management of severe community-acquired septic meningitis in adults: from emergency department to intensive care unit. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 108: 112-8. PMID 19251546 DOI: 10.1016/S0929-6646(09)60041-3  0.303
2008 Ma WL, Ma CL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 135: 947-55, 955.e1-5. PMID 18639551 DOI: 10.1053/J.Gastro.2008.05.046  0.775
2008 Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology (Baltimore, Md.). 47: 1924-35. PMID 18449947 DOI: 10.1002/Hep.22252  0.722
2008 Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. International Journal of Cancer. 123: 195-201. PMID 18386814 DOI: 10.1002/Ijc.23481  0.637
2007 Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocrine-Related Cancer. 14: 633-43. PMID 17914094 DOI: 10.1677/ERC-07-0073  0.394
2007 Juang SH, Lung CC, Hsu PC, Hsu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang L, Chen TS, Chen SF, Fu KC, Hsu CL, et al. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. Molecular Cancer Therapeutics. 6: 193-202. PMID 17237279 DOI: 10.1158/1535-7163.MCT-06-0482  0.367
2005 Ting HJ, Bao BY, Hsu CL, Lee YF. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine. 26: 1-9. PMID 15805579 DOI: 10.1385/Endo:26:1:001  0.762
2005 Hsu CL, Chen KY, Chang CH, Jerng JS, Yu CJ, Yang PC. Timing of tracheostomy as a determinant of weaning success in critically ill patients: a retrospective study. Critical Care (London, England). 9: R46-52. PMID 15693966 DOI: 10.1186/cc3018  0.326
2005 Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C. Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Molecular Endocrinology (Baltimore, Md.). 19: 350-61. PMID 15514032 DOI: 10.1210/Me.2004-0190  0.817
2005 Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. The Prostate. 63: 117-30. PMID 15486994 DOI: 10.1002/Pros.20170  0.652
2004 Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, Chang C. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 279: 33438-46. PMID 15166229 DOI: 10.1074/Jbc.M401781200  0.822
2004 Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, Chang C. Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Molecular and Cellular Biology. 24: 2202-13. PMID 14966297 DOI: 10.1128/Mcb.24.5.2202-2213.2004  0.696
2003 Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang X, Chang C. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. The Journal of Biological Chemistry. 278: 23691-8. PMID 12714604 DOI: 10.1074/Jbc.M211908200  0.789
2002 Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y, Chang C. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. The Journal of Biological Chemistry. 277: 15426-31. PMID 11856738 DOI: 10.1074/Jbc.M111218200  0.6
2001 Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C. Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. The Journal of Biological Chemistry. 276: 40417-23. PMID 11509567 DOI: 10.1074/Jbc.M104765200  0.547
2000 Yeh S, Sampson ER, Lee DK, Kim E, Hsu CL, Chen YL, Chang HC, Altuwaijri S, Huang KE, Chang C. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer. Journal of the Formosan Medical Association = Taiwan Yi Zhi. 99: 885-94. PMID 11155740  0.796
2000 Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 11256-61. PMID 11016951 DOI: 10.1073/Pnas.190353897  0.795
Show low-probability matches.